USA –
WORCESTER, MA, iVexSol, a rapidly growing lentiviral vector (LVV) manufacturing company, has scored a $13 million Series A funding round.
A total of $15.2M has been raised to date from current investors Casdin Capital, LLC , and BioLife Solutions (NASDAQ:BLFS) and a third undisclosed lead investor. Funds will be used to establish a cGMP manufacturing facility in Lexington, MA for stable LVV producer cell line master banks and commercial-grade LVV.
iVexSol is a viral vector manufacturing company founded on a proprietary, next-generation, stable lentiviral vector production process that transforms the way these essential gene-delivery vehicles are made. Its technology will greatly reduce the complexity, cost, and development time of these critical reagents, thereby accelerating the development and enabling greater access to life-changing cell and gene therapies. For more information visit www.ivexsol.com.
iVexSol
17 Briden St – Worcester, MA 01650
